PHARMACYTE BIOTECH, INC. (PMCB) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-07-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-07-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 356.14K USD | Research and Development Expense |
| Revenue | 0.00 USD | |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -7.01M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | $356.14K | $0.00 | (m) | $-7.01M | (m) | (m) | (m) | (m) | (m) |
| 2026-04-30 | $391.30K | $0.00 | $892.50K | $-6.85M | (m) | (m) | (m) | (m) | (m) |
| 2026-01-31 | $456.09K | $0.00 | $1.37M | $-5.38M | (m) | (m) | (m) | (m) | (m) |
| 2025-10-31 | $481.17K | $0.00 | $257.79K | $-4.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-07-31 | $437.56K | $0.00 | $316.45K | $-3.96M | (m) | (m) | (m) | (m) | (m) |
| 2025-04-30 | $438.42K | $0.00 | $478.64K | $-4.38M | (m) | (m) | (m) | (m) | (m) |
| 2025-01-31 | $405.87K | $0.00 | $-260.00K | $-6.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-10-31 | $414.40K | $0.00 | $341.83K | $-7.41M | (m) | (m) | (m) | (m) | (m) |
| 2024-07-31 | $398.96K | $0.00 | $222.68K | $-7.71M | (m) | (m) | (m) | (m) | (m) |
| 2024-04-30 | $407.43K | $0.00 | $0.00 | $-8.52M | (m) | (m) | (m) | (m) | (m) |
| 2024-01-31 | $399.12K | $0.00 | $0.00 | $-6.26M | (m) | (m) | (m) | (m) | (m) |
| 2023-10-31 | $317.78K | $0.00 | $667.00 | $-5.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-07-31 | $413.75K | $0.00 | $4.58K | $-6.85M | (m) | (m) | (m) | (m) | (m) |
| 2023-04-30 | $468.54K | $0.00 | $7.33K | $-6.46M | $0.00 | (m) | (m) | (m) | Reported |
| 2023-01-31 | $636.73K | $0.00 | $10.08K | $-7.06M | $0.00 | (m) | (m) | (m) | Reported |
| 2022-10-31 | $749.37K | $0.00 | $17.70K | $-6.36M | $0.00 | (m) | (m) | (m) | Reported |
| 2022-07-31 | $706.60K | $0.00 | $24.84K | $-5.05M | $42.00 | (m) | (m) | -120220.74× | Reported |
| 2022-04-30 | $690.94K | $0.00 | $33.15K | $-4.39M | $509.00 | (m) | (m) | -8628.71× | Reported |
| 2022-01-31 | $757.14K | $0.00 | $41.45K | $-3.92M | $1.55K | (m) | (m) | -2530.18× | Reported |
| 2021-10-31 | $773.19K | $0.00 | $81.73K | $-3.82M | $1.80K | (m) | (m) | -2124.57× | Reported |
| 2021-07-31 | $789.29K | $0.00 | $138.00K | $-3.76M | $3.13K | (m) | (m) | -1204.69× | Reported |
| 2021-04-30 | $916.25K | $0.00 | $194.26K | $-3.62M | $3.05K | (m) | (m) | -1189.42× | Reported |
| 2021-01-31 | $693.63K | $0.00 | $242.16K | $-3.34M | $2.46K | (m) | (m) | -1357.43× | Reported |
| 2020-10-31 | $632.84K | $0.00 | $293.84K | $-3.46M | $2.21K | (m) | (m) | -1563.98× | Reported |
| 2020-07-31 | $499.46K | $0.00 | $331.24K | $-3.57M | $841.00 | (m) | (m) | -4249.70× | Reported |
| 2020-04-30 | $301.22K | $0.00 | $368.65K | $-3.83M | $453.00 | (m) | (m) | -8446.79× | Reported |
| 2020-01-31 | $221.58K | $0.00 | $357.50K | $-4.25M | (m) | (m) | (m) | (m) | (m) |
| 2019-10-31 | $167.43K | $0.00 | $318.64K | $-4.05M | (m) | (m) | (m) | (m) | (m) |
| 2019-07-31 | $264.59K | $0.00 | $305.99K | $-4.02M | (m) | (m) | (m) | (m) | (m) |
| 2019-04-30 | $460.05K | $0.00 | $293.33K | $-4.10M | (m) | (m) | (m) | (m) | (m) |
| 2019-01-31 | $694.16K | $0.00 | $337.59K | $-4.38M | (m) | (m) | (m) | (m) | (m) |
| 2018-10-31 | $1.44M | $0.00 | $421.30K | $-5.73M | (m) | (m) | (m) | (m) | (m) |
| 2018-07-31 | $1.84M | $0.00 | $500.83K | $-6.51M | (m) | (m) | (m) | (m) | (m) |
| 2018-04-30 | $2.00M | $0.00 | $580.36K | $-6.98M | $0.00 | (m) | (m) | (m) | Reported |
| 2018-01-31 | $1.92M | $0.00 | $717.09K | $-6.69M | $483.00 | (m) | (m) | -13846.61× | Reported |
| 2017-10-31 | $1.70M | $0.00 | $619.92K | $-5.94M | $614.00 | (m) | (m) | -9673.07× | Reported |
| 2017-07-31 | $1.43M | $0.00 | $520.20K | $-5.10M | $970.00 | (m) | (m) | -5256.87× | Reported |
| 2017-04-30 | $1.18M | $0.00 | $420.48K | $-4.44M | $1.54K | (m) | (m) | -2886.38× | Reported |
| 2017-01-31 | $1.25M | $0.00 | $287.52K | $-4.42M | $1.29K | (m) | (m) | -3411.94× | Reported |
| 2016-10-31 | $1.24M | $0.00 | $294.80K | $-4.93M | $1.29K | (m) | (m) | -3820.62× | Reported |
| 2016-07-31 | $1.43M | $0.00 | $329.60K | $-5.59M | $1.13K | (m) | (m) | -4955.87× | Reported |
| 2016-04-30 | $1.41M | $0.00 | $405.08K | $-6.07M | $1.19K | (m) | (m) | -5099.19× | Reported |
| 2016-01-31 | $4.02M | $0.00 | $476.88K | $-8.92M | $-353.00 | (m) | (m) | (m) | Reported |
| 2015-10-31 | $3.72M | $0.00 | $508.88K | $-8.00M | $1.04K | (m) | (m) | -7703.44× | Reported |
| 2015-07-31 | $3.63M | $0.00 | $796.45K | $-13.12M | $2.92K | (m) | (m) | -4496.25× | Reported |
| 2015-04-30 | $3.48M | $0.00 | $735.19K | $-13.70M | $4.94K | (m) | (m) | -2773.49× | Reported |
| 2015-01-31 | (m) | $0.00 | (m) | $-25.73M | $-6.45K | (m) | (m) | (m) | Reported |
| 2014-10-31 | (m) | $0.00 | (m) | $-24.96M | $-4.20K | (m) | (m) | (m) | Reported |
| 2014-07-31 | (m) | $0.00 | (m) | $-19.16M | $-2.67K | (m) | (m) | (m) | Reported |
| 2014-04-30 | (m) | $0.00 | (m) | $-18.98M | $5.03K | (m) | (m) | -3773.19× | Reported |
| 2014-01-31 | (m) | $0.00 | (m) | $-2.99M | $13.07K | (m) | (m) | -228.44× | Reported |
| 2013-10-31 | (m) | $-753.00 | (m) | $-2.65M | $13.29K | (m) | (m) | -199.12× | Reported |
| 2013-07-31 | (m) | $5.53K | $1.87M | $-2.55M | $76.95K | (m) | 33739.12% | -33.09× | Reported |
| 2013-04-30 | (m) | $12.16K | $984.70K | $-1.68M | $112.66K | (m) | 8097.83% | -14.95× | Reported |
| 2013-01-31 | (m) | $18.84K | $953.22K | (m) | $255.96K | (m) | 5059.30% | (m) | Reported |
| 2012-10-31 | (m) | $39.87K | $1.19M | (m) | $287.74K | (m) | 2990.54% | (m) | Reported |
| 2012-07-31 | (m) | $53.42K | $1.35M | (m) | $272.08K | (m) | 2533.13% | (m) | Reported |
| 2012-04-30 | (m) | $66.56K | $1.57M | (m) | $241.25K | (m) | 2359.27% | (m) | Reported |
| 2012-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-30 | (m) | (m) | $130.00K | (m) | $171.66K | (m) | (m) | (m) | Reported |
| 2011-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |